HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TRAVATAN Z ® safely and effectively. See full prescribing information for TRAVATAN Z ®. 

TRAVATAN Z ® (travoprost ophthalmic solution) 0.004% for topical ophthalmic use 

Initial U.S. Approval: 2001 

INDICATIONS AND USAGE 

TRAVATAN Z® is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (1) 

DOSAGE AND ADMINISTRATION 

One drop in the affected eye(s) once daily in the evening (2) 

DOSAGE FORMS AND STRENGTHS 

Ophthalmic solution containing travoprost 0.04 mg/mL (3) 

CONTRAINDICATIONS 

None (4) 

WARNINGS AND PRECAUTIONS 

Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent (5.1) 

Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible (5.2) 

ADVERSE REACTIONS 

Most common adverse reaction (30% to 50%) is conjunctival hyperemia (6.1) 

To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

USE IN SPECIFIC POPULATIONS 

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use (8.4) 

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2017

FULL PRESCRIBING INFORMATION: CONTENTS*

 1 INDICATIONS AND USAGE 

 2 DOSAGE AND ADMINISTRATION 

 3 DOSAGE FORMS AND STRENGTHS 

 4 CONTRAINDICATIONS 

 5 WARNINGS AND PRECAUTIONS 

 5.1 Pigmentation 

 5.2 Eyelash Changes 

 5.3 Intraocular Inflammation 

 5.4 Macular Edema 

 5.5 Angle-closure, Inflammatory or Neovascular Glaucoma 

 5.6 Bacterial Keratitis 

 5.7 Use with Contact Lenses 

 6 ADVERSE REACTIONS 

 6.1 Clinical Trials Experience 

 6.2 Postmarketing Experience 

 8 USE IN SPECIFIC POPULATIONS 

 8.1 Pregnancy 

 8.3 Nursing Mothers 

 8.4 Pediatric Use 

 8.5 Geriatric Use 

 8.6 Hepatic and Renal Impairment 

 11 DESCRIPTION 

 12 CLINICAL PHARMACOLOGY 

 12.1 Mechanism of Action 

 12.3 Pharmacokinetics 

 13 NONCLINICAL TOXICOLOGY 

 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 

 14 CLINICAL STUDIES 

 16 HOW SUPPLIED/STORAGE AND HANDLING 

 17 PATIENT COUNSELING INFORMATION 

* Sections or subsections omitted from the full prescribing information are not listed. Close 

1 INDICATIONS AND USAGE